Metsä Tissue, part of Metsä Group, is working to implement a strategy which envisages an operational review with the aim of improving internal efficiency, reducing complexity and concentrating on tissue business.
Within the framework of this review in the second quarter of 2019, the company will record a reduction in value, mainly linked to the start-up, of about 102 million euros. Furthermore, the company will show a restructuring provision of about 5 million euros relating to the co-management negotiations in progress and those already concluded.
Such accounts have a negative impact on the share capital of Metsä Tissue of about 8 percentage points. The impact on the entire share capital of Metsä Group is minimal.